NEW YORK, Dec. 7, 2017 /PRNewswire/ -- Edwards
Lifesciences Corporation (NYSE: EW), the global leader in
patient-focused innovations for structural heart disease and
critical care monitoring, announced today that its Board of
Directors recently authorized a new share repurchase program to
acquire up to an additional $1 billion of the company's
outstanding common shares.
Separately, the company also announced that in November it
entered into an accelerated share repurchase agreement to acquire
$150 million of Edwards' common
stock. Upon entering into the agreement, Edwards received and
retired an initial delivery of 1.1 million shares. In
addition, earlier in the fourth quarter, Edwards repurchased
approximately $100 million of common
stock.
About Edwards Lifesciences
Edwards Lifesciences, based
in Irvine, Calif., is the global
leader in patient-focused medical innovations for structural heart
disease, as well as critical care and surgical monitoring. Driven
by a passion to help patients, the company collaborates with the
world's leading clinicians and researchers to address unmet
healthcare needs, working to improve patient outcomes and enhance
lives. For more information, visit www.Edwards.com and follow us on
Twitter @EdwardsLifesci.
View original content with
multimedia:http://www.prnewswire.com/news-releases/edwards-lifesciences-board-approves-new-1-billion-share-repurchase-program-300568177.html
SOURCE Edwards Lifesciences Corporation